Prime Medicine
Yune Kunes has extensive work experience in the pharmaceutical industry, particularly in analytical development and program management. They began their career at Millennium Pharmaceuticals in 1999 as a Sr. Scientist in antibody and small molecule drug discovery and development. In 2005, they joined AbbVie as an Associate Director in biologics CMC development and cell line development. They later worked at Shire as a Director in bioanalytical development from 2011 to 2015. Yune then served as VP and Head of Analytical Development and Senior Director of Program Management at Fortress Biotech from 2015 to 2018. They went on to become the VP of Analytical Development at TG Therapeutics from 2018 to 2022. Currently, Yune holds the position of VP and Head of Analytical Development, Formulation, and Early Stage QC at Prime Medicine, Inc. since 2022.
Yune Kunes holds a B. Eng. degree in Chemical Engineering and Applied Chemistry from Tsinghua University. Additionally, they have pursued a Ph.D. in Biochemistry at The Graduate Center, City University of New York. Following completion of their Ph.D., Yune Kunes went on to further their education by undertaking a postdoctoral position in Cell Biology at Harvard Medical School.
This person is not in any offices
Prime Medicine
4 followers
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.